 
  
Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy  
 
[STUDY_ID_REMOVED] 
 
Clinical Protocol 
 
14 September 2015 
 
 
E7034   Confidential  
THESE DOCUMENTS ARE THE PROPERTY OF BOSTON SCIENTIFIC CORP. AND SHALL NOT BE REPRODUCED, 
DISTRIBUTED, DISCLOSED OR USED FOR MANUFACTURE OR SALE OF APPARATUS WITHOUT THE EXPRESS WRITTEN 
CONSENT OF BOSTON SCIENTIFIC CORP.  
 
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 1 of 43 
  
 Randomized Controlled Trial Comparing Covered and Uncovered Biliary Self 
Expanding Metal Stents (SEMS) for Pre -operative Drainage During Neoadjuvant 
Therapy in Patients  with Pancreatic Cancer  
 
Short Title  
Pre-operative Biliary SEMS RCT During  Neoadjuvant Therapy 
 
 
CLINICAL PROTOCOL  
 
E7034 
 
 
  
Sponsored By  
Boston Scientific Corporation 
100 Boston Scientific Way 
Marlborough, MA 01752-1234 
USA 
 
 
 
 
 
This protocol contains confidential information  for use by the Investigators and their 
designated representatives participating in this clinical investigation. It should b e held 
confidential and maintained in a secure location.  
Do not copy or distribute without written permission from Boston Scientific Corporation. 
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 2 of 43 
  
 
Contact Information  
Role  Contact  
Clinical Contact  Nguyet Labenski  
Clinical Project Specialist  
Endoscopy 
Boston Scientific Corporation 100 Boston Scientific Way Marlborough, MA 01752-1234 
Phone:  508-683-4065 
Email:   nguyet.labenski@bsci.com 
 
Lead Investigator s Professor Hiroyuki Isayama, MD, PhD.  
Department of Gastroenterology, Graduate School of Medicine 
The University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655, Japan  
 Professor Dong -Wan Se o, MD, PhD. 
Asan Medical Center  
88, O lympic -Ro 43-Gil, Songpa- Gu,  
Seoul 138-736, K orea 
 
 
Original Release: December 11, 2013 
Current Version:   September 14, 2015 
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 3 of 43 
 Do not copy or distribute without written permission. 
 
Investigatorâ€™s Signature Page 
  
STUDY TITLE:  Randomized Controlled Trial Comparing Covered and 
Uncovered Biliary Self Expanding Metal Stents (SEMS) for Pre-operative Drainage During Neoadjuvant Therapy in  
Patients with P ancreatic Cancer  
STUDY CENTER:  _____________________________________________  
(Print name of study center)  
 
PROTOCOL VERSION : AE 
 
 We, the undersigned, have read and understand the protocol specified above and agree on its content.  We agree to perform and conduct the study as described in the protocol.  In addition, when applicable, we agree to enlist sub-investigators who also agree to perform and conduct the study as described in the protocol.   
 
 
Principal Investigator  
Print name: 
  
  
Co-Principal Investigator (if applicable)  
Print name: 
    
 
Date  
 
     
Date  
 
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 4 of 43 
 Protocol Synopsis 
 
Full Title  Randomized Controlled Trial Comparing Covered and Uncovered Biliary 
Self Expanding Metal Stents (SEMS)  for Pre -operative Drainage During 
Neoadjuvant Therapy in  Patients with P ancreatic  Cancer  
Abbreviated 
Title  Pre-operative Biliary SEMS  RCT  During Neoadjuvant Therapy 
Primary Objective  To demonstrate non -inferiority of Fully Covered biliary SEMS to 
Uncovered biliary SEMS in biliary drainage for the pre- operative 
management of biliary obstructive symptoms caused by pancreatic cancer in patients undergoing neoadjuvant therapy. 
Devices     Stent Type:  
FC Arm:  WallFlex Biliary RX Fully Covered S tent  
       UC Arm:  WallFlex Biliary RX Uncovered Stent  
Stent Diameter:  
8mm or 10mm 
Stent Length:  
40mm, 60mm, or 80mm 
The stent length will be selected to be such that the stent length should be long enough to cover the stricture completely but to leave sufficient 
length of normal bile duct for subsequent anastomosis.  
Device Indication The WallFlex Biliary RX Fully Covered Stent is  indicated for use in the 
palliative treatment of biliary strictures produced by malignant neoplasms, relief of malignant biliary obstruction prior to surgery, and for treatment of benign biliary strictures . 
 The WallFlex Biliary RX Uncovered Stent is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms  
and relief of malignant biliary obstruction prior to surgery.  
Study Design  Prospective, multi -center,  randomized, post -market  
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 5 of 43 
 Primary 
Endpoint  Successful pre -operative biliary drainage  defined as absence of 
reinterventions for the management of biliary obstructive symptoms.  
â€¢ For patients undergoing surgery: from stent placement until surgery 
â€¢ For patients transitioning to palliative management: from stent 
placement until transition to palliation  
Secondary Endpoints  
 
           1. Occurrence and severity of adverse events  related to the stent and/or 
stenting procedure  
2. Occurrence and severity of surgical complications  
3. Occurrence and severity of peri -surgical complications (up to 30 days 
after surgery)  
4. Ability to deploy the stent in  a satisfactory position across the stricture 
(Stent Placement Success)  
5. Improvement of bi liary obstructive symptoms during stent indwell at 
Week 1 and Monthly until surgery or transition to palliation  as 
applicable, compared to Baseline 
6. Improvement of Laboratory Liver Function Tests (LFTs)  until surgery 
for patients undergoing surgery, and at Week 1 and Monthly until 
transition to palliation, and at 1 year after stent placement for patients not undergoing surgery. 
7. Biliary Reintervention  rate  
8. Ability to complete neoadjuvant therapy as intended without stent related interruptions of neoadjuvant therapy  
9. Stent migration rate  
10. Assessment by surgeon of interference, if any, of SEMS on time to surgery and/or success of pancreaticoduodenectomy  
11. For patients transitioning to palliative management:  Successful biliary drainage defined as absence of reinterventions for the management of biliary obstructive symptoms  from stent placement  to 
1 year after stent placement  
Hypothesis  Statistical testing will be performed to determine if the rate of success when 
using the Fully Covered SEMS is non-inferior to the rate of success when 
using the Uncovered SEMS. The following hypothesis will be tested: 
Ho: Ï€UCâˆ’Ï€FC â‰¥âˆ†  (Inferior)  
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 6 of 43 
 Ha: Ï€UCâˆ’Ï€FC <âˆ†  (Non -inferior)  
where Ï€FC  and Ï€UC  are the probabilities of having success in the WallFlex 
Fully Covered Stent and WallFlex Uncovered Stent arms respectively, and 
âˆ† is defined as the non -inferiority margin.  
The sample size was calculated for the test using an exact non- inferiority  
test. The assumed success rates for both study arms and the non- inferiority 
margin are guided by t he following analysis of literature:  
The success rate estimate is extracted from a full literature search which yielded nine articles ( 377 patients ) 
2, 7, 21, 24, 25, 27 , 29-31 on the use of metal 
stents for pre -operative biliary drainage.  The nine articles yielded a success 
rate estimate of  84.6 % with a 95% CI of (80.5% - 87.9%).  
Each arm is assumed to have a success rate of 8 0.5%.  The non- inferiority 
margin (Î”) is set at 20%.  Given these assumptions a sample size of 51 x 2 = 102 patients provide 80% power to reject the null hypothesis. If the p-
value calculated for the test is below 0.05 it will be concluded that the test is significant, and that the WallFlex Fully Covered stent is non- inferior to 
the WallFlex Uncovered stent.   
An additional 20% of patients  will be enrolled to compensate for possible 
loss of patients  to follow-up, giving a total sample size of 122 patients . 
 
Planned 
Number of 
Patients  122 
Planned Number of 
Sites  6-12 
Key Inclusion Criteria  1. Age 18 or older  
2. Patient indicated for biliary metal stent placement for the treatment of 
jaundice and/or cholestasis  
3. Willing and able to comply with the study procedures and provide written informed consent to participate in the study 
4. Suspicion of pancreatic adenocarcinoma  
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 7 of 43 
 5. Likely indicated for neoadjuvant treatment 
6. Distal biliary obstruction consistent with pancreatic cancer  
7. Location of distal biliary obstruction such that it would allow the 
proximal end of a stent to be positioned at least 2 cm from the hilum 
8. Endoscopic and surgical treatment to be provided at the same 
institution  
Key Exclusion Criteria  1. Benign biliary strictures  
2. Malignancy secondary to Intraductal  Papillary Mucinous Neoplasm  
3. Surgically altered  anatomy where ERCP is not possible  
4. Previous biliary drainage using a SEMS or multiple plastic stents  
5. Contraindications for endoscopic techniques 
6. Patients who are currently enrolled in another investigational trial that would directly interfere with the current study 
7. Pregnancy  
Visits  â€¢ Screening  
â€¢ Baseline  
â€¢ Stent Placement Procedure Visit 
â€¢ Pre-Operative Follow -Up Visit (Week 1 and Monthly until Surgery or 
Transition to Palliation ) 
â€¢ Biliary Reintervention Visit (as needed)  
â€¢ Curative Intent Surgery 
â€¢ Transition to Palliative Management Visit (as needed)  
â€¢ Post- Operative Follow -Up Visit (30 day Post-Surgery visit)  
â€¢ Long Term Follow- Up Visit (1 year after initial treatment for patients  
that have transitioned to palliation or 1 year post- stent placement for 
patients  that have not undergone surgery or transitioned to palliation 
(with or without Neoadjuvant Therapy )) 
 
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 8 of 43 
  
TABLE OF CONTENTS  
TITLE PAGE  .................................................................................................................................................... 1 
1.  INTRODUCTION  .................................................................................................................... 11  
2.  OBJECTIVES  ......................................................................................................................... 13  
3.  DESIGN  ................................................................................................................................. 13  
3.1. Scale and Duration ................................................................................................. 13  
3.2. Treatment Assignment ........................................................................................... 13  
4.  ENDPOINTS  ........................................................................................................................... 14  
4.1.  Primary Endpoint .................................................................................................... 14  
4.2.  Secondary Endpoints ............................................................................................... 14  
5.  PATIENT  SELECTION  ........................................................................................................... 15  
5.1. Inclusion Criteria  ................................................................................................... 15  
5.2. Exclusion Criteria  .................................................................................................. 15  
6.  STUDY DEVICES  ................................................................................................................... 16  
7.  STUDY VISITS  ....................................................................................................................... 17  
7.1. Visit Schedule  ......................................................................................................... 17  
7.2. Screening â€“ Office Visit  ......................................................................................... 20  
7.3. Baseline Visit â€“ Office Visit  ................................................................................... 20  
7.4. Tumor Diagnosis, Staging, and Characteristics â€“ Office Visit  .......................... 21  
7.5. Planned Neoadjuvant Therapy  ............................................................................. 21  
7.6. Stent Placement Procedure Visit â€“ Office Visit  ................................................... 21  
7.7. Pre-Operative Follow -Up Visit â€“ Phone and/or Office Visit  .............................. 21  
7.8. Biliary Reintervention Visit (Arm 1 or 2) â€“ as needed  ....................................... 22  
7.9. Curative Intent Surgery â€“ Office Visit  ................................................................. 22  
7.10.  Transition to Palliative Management Visit (as needed) â€“ Phone and/or Office 
Visit  .......................................................................................................................... 22  
7.11.  Post-Operative Follow -Up Visit (30 days) â€“ Phone and/or Office Visit  ............ 23  
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 9 of 43 
 7.12.   Long Term Follow-Up Visit (1 year after initial treatment for patients that have 
transitioned to palliation or 1 year post- stent placement for patients that have not 
undergone surgery or transitioned to palli ation (with or without Neoadjuvant 
Therapy) â€“ Phone and/or Office Visit  .................................................................. 23  
7.13.    Study Completion ................................................................................................ 24  
8.  STATISTICAL CONSIDERATIONS  .......................................................................................... 24  
8.1 Hypotheses  .............................................................................................................. 24  
8.2 Sample Size  ............................................................................................................. 24  
8.3 Analysis Populations .............................................................................................. 25  
8.4 Data Analysis .......................................................................................................... 25  
9.   POTENTIAL RISKS AND BENEFITS  ...................................................................................... 27  
9.1.  Anticipated Adverse Device Effects  ....................................................................... 27  
9.2.   Anticipated Surgical Adverse Events .................................................................... 27  
9.3.   Risk Minimization Actions ..................................................................................... 28  
9.4.  Anticipated Benefits ................................................................................................. 28  
9.5.  Risk to Benefit Rationale......................................................................................... 28  
10.  SAFETY REPORTING  .......................................................................................................... 28  
10.1.  Definitions and Classification  ............................................................................... 28  
10.2.  Relationship to Study Device(s) ............................................................................ 30  
10.3.  Investigator Reporting Requirements ................................................................. 31  
10.4.  Bos ton Scientific Device Deficiencies  ................................................................... 31  
10.5.  Reporting to Regulatory Authorities / IRBs / Investigators .............................. 32  
11.  BIBLIOGRAPHY  .................................................................................................................. 32  
APPE NDIX  B: SPONSOR  REQUIRED  PROTOCOL  SECTIONS  .................................. 34  
B.1.   DATA MANAGEMENT  ....................................................................................................... 34  
B.2.   AMENDMENTS  .................................................................................................................. 35  
B.3.    DEVICE /EQUIPMENT ACCOUNTABILITY  ......................................................................... 35  
B.4.   DEVIATIONS  ...................................................................................................................... 35  
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 10 of 43 
 B.5.   COMPLIANCE  .................................................................................................................... 36  
B.6.   INSTITUTIONAL REVIEW BOARD /ETHICS COMMITTEE  .................................................. 38  
B.7.   MONITORING  .................................................................................................................... 39  
B.8.   INSURANCE  ....................................................................................................................... 39  
B.9.   INFORMED CONSENT  ........................................................................................................ 39  
B.10.   PUBLICATION POLICY  .................................................................................................... 40  
B.11.  DEFINITIONS OF COMPLI CATION CRITERIA (PER VAN DER GAAG ARTICLE ): .............. 41  
B.12.   ABBREVIATIONS AND DEFINITIONS  ............................................................................... 42  
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 11 of 43 
 1.  Introduction  
 
In the United States, pancreatic cancer is the second most common digestive cancer1  and the 
fourth leading cause of death with a 5-year survival rate of only 5%.2   Globally, there are an 
estimated 216,000 new cases of pancreatic cancer annually.3  Pancreatic cancer , which is the 
most prevalent peri- ampullary cancer,  is located in the head of the pancreas in approximately 
two thirds of cases.4   Patients with pancreatic cancer presenting with biliary obstruction can be 
stratified into patients with unresectable tumors, with borderline resectable or locally advanced tumors, or with resect able tumors.  More than 70% of pancreatic cancer patients are poor 
candidates for surgery or are deemed unresectable
5; the WallFlex Biliary SEMS are currently 
indicated for use in these patients.  Some patients may be candidates for PD with curative intent, however, 25%-41% do not undergo PD as planned due to disease progression, evolving comorbidities, or decline in performance status during the time between diagnosis and scheduled PD.
6-8  Pre-operative neoadjuvant chemo 
or chemoradiation therapy is increasingly considered in the treatment of patients with resectable or borderline resectable pancreatic cancer.  The aim is to downsize tumors and improve the likelihood of a margin- free (R0) resection, to provide early treatment of micrometastases, and 
ultimately to optimize post-operative survival.
9-13 In a recent report, 32 of 84 (38%) patients with 
borderline resectable disease underwent a PD after neoadjuvant therapy, with R0 resection achieved in 94% of patients and resulting median survival of 40 months post PD.
13   In another 
report on 132 patients with resectable pancreatic cancer, it was found that combined neoadjuvant chemoradiation and PD yielded a median survival of 21 months from the time of tissue diagnosis, and at a median follow-up of 14 months 42 of 132 patients (32%) survived with no clinical or radiographic evidence of disease.
14   The duration of neoadjuvant chemoradiation 
typically ranges from 2 to 7 months6,14 and tends to require a subsequent pre- operative resting 
and restaging period which can last up to several months.7   
  Periampullary cancer including cancer in the head of the pancreas is associated with biliary obstructive symptoms such as jaundice at initial patient presentation in approximately 50% -70% 
of patients.
7  Biliary obstruction requires biliary decompression.6,15  Indeed, if left untreated, 
prolonged biliary obstruction leads to coagulopathy, malabsorption and consequent progressive malnutrition, pruritus, hepatic dysfunction, recurrent attacks of cholangitis and altered bile salt metabolism.
16,17  Pre-operative biliary drainage provides relief of biliary obstructive symptoms 
during neoadjuvant therapy18,19 and improves post PD tissue healing in response to reduced 
bilirubin levels.20  Without such pre- operative drainage patients may lose their resectable or 
potentially resectable status due to interruption of the neoadjuvant therapy and/or delayed scheduling of the intended PD.  In addition, for patients receiving 3 to 4 months of neoadjuvant therapy, biliary drainage may be beneficial since some chemotherapeutic agents require adequate liver function and pre-operative immunosuppression can increase susceptibility to the risks of cholangitis if bile duct drainage is inadequate.
21  If severely jaundiced patients do undergo PD, 
they may be at risk of significant post- operative complications36 such as renal failure and 
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 12 of 43 
 sepsis.22,23  It is therefore important that pre -operative biliary drainage be provided during 
neoadjuvant therapy and the subsequent restaging and resting period.  
 Pre-operative biliary drainage has traditionally be en achieved with plastic stents.  However, these 
stents have been associated with high complication rates and relatively low success rates in pre -
operative management of biliary obstruction .
6,21,24 -27  Plastic stents used for pre-operative 
drainage can occlude within a few weeks which in turn may necessitate additional pre- operative 
ERCPs21.  The use of SEMS provides a viable alternative that has been shown to be superior to 
plastic stents for pre -operat ive biliary drainage due to lower rates of occlusion, fewer episodes of 
cholangitis/cholestasis, fewer additional ERCPs before surgery, and longer stent patency resulting in most patients completing  uninterrupted neoadjuvant chemoradiation therapy and preventing delays of surgery.
1,24,27 
 A literature review was conducted of clinical success of pre -operative biliary drainage using 
plastic or metal biliary stenting including all SEMS types used.  Two associated meta -analyses 
were generated based on published reports of ratios of the number of patients experiencing clinical success in pre- operative biliary drainage without stent related complications over the 
total number of stented patients.  A meta -analysis representing a total of 429 patients in six  
public ations using plastic biliary stents  yielded a biliary drainage success rate estimate of 45.9% 
[95% CI, 34.7% - 57.5 %].
2,6, ,24-27  A meta -analysis representing a total of 377 patients in nine 
publications using SEMS yielded a biliary drainage success rate estimate of  8 4.6% [95% CI, 
80.5% - 87.9%].2, 7, 21, 24, 25, 27 , 29-31 In patients who do ultimately undergo PD with curative intent, 
the SEMS is removed en -bloc inside the surgical specimen.  Six  of the 9 publications reporting 
on the use of pre-operative biliary drainage using SEMS state explicitly on the fact  that SEMS do 
not interfere with successful PD  and could be easily removed intra-operatively without 
complications. 7,21,24,25,27,31  Some studies have reported an increased risk of post- operative wound 
infection13,33-35, but there were no other reported increases in  intra-operative or post- operative 
complications related to the use of SEMS.  In addition, SEMS could be easily removed intra-operatively without complications.
20, 27-30 
 
Pre-operative biliary drainage (PBD) prior to Pancreaticoduodenectomy (PD) continues to be 
routine in many centers despite retrospective data showing that P BD increases post -operative 
wound infection.13,33-35  It was shown that these post-operative wound infections were classified 
on a grading scale of 1-5, with all reported occurrences  rated as either 1  (oral medication and 
bedside intervention) or 2 (IV medication, TPN, enteral nutrition, or blood), and managed non-invasively.
33  Other studies have also reported an inc rease in post -operative wound infection in 
the PBD group, but have indicated that although there is an increase in length of hospitalization, the length of time under anesthesia, amount of blood loss, and transfusion requirements were unaffected .
32,34 
 In line with the findings summarized above, SEMS have emerged as an alternative to using plastic stents for pre -operative biliary drainage.  Several opinion- leading centers in this field 
have adopted SEMS drainage as their standard of practice in PD -bound patients undergoing 
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 13 of 43 
 neoadjuvant therapy. Most recently leading cancer centers7, 21, 3 2  have published that the use of 
pre-operative biliary SEMS, and not plastic stents, in patients with resectable or potentially 
resectable pancreatic or periampullary cancer receiving neoadjuvant therapy is effective and safe.  
Boston Scientific is proposing a multi- center, randomized , prospe ctive , post- market  trial on the 
use of SEMS for biliary drainage in patients with pancreatic cancer  undergoing neoadjuvant 
therapy.    
2.  Objectives  
 
The purpose of this clinical trial is to demonstrate non-inferiority of Fully Covered biliary SEMS to Uncovered biliary SEMS in biliary drainage for the pre- operative management of biliary 
obstructive symptoms caused by pancreatic cancer in patients undergoing neoadjuvant therapy. 
3.  Design  
 This is a post- market, prospective , multi- center, randomized study e valuating covered and 
uncovered SEMS for p re-operative management of patients with pancreatic  cancer  undergoing 
neoadjuvant therapy. 
3.1. Scale and Duration  
Patients  that have gone to surgery will be followed for 30 days post-surgery.  For patients that 
have transitioned to palliation, the Long Term Follow- Up V isit will occur one (1) year after 
initial treatment.   Patients that have not gone to surgery and have not transitioned to palliation 
(with or without Neoadjuvant Therapy) will be followed up to 1 year post- stent placement.   
There will be 6-12 participating centers  with anticipated enrollment of 122 patients.  
 At each investigational center, there will be one principal investigator (PI) who will be an 
endoscopist.  Where possible at least one co -investigator should be a pancreaticobiliary surgeon.   
3.2. Treatment Assignment  
Patients will be randomized at Screening  in equal proportions of 1:1 ratio between Arm 1 and 
Arm 2 as follows: 
â€¢ Arm 1: WallFlex Biliary RX Fully Covered Stent  
 
â€¢ Arm 2: WallFlex Biliary RX Uncovered Stent  
 Block randomization through an online database system will be used.  Randomization will be stratified by study center.  
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 14 of 43 
 4.  Endpoints   
4.1.  Primary Endpoint 
Successful pre -operative biliary drainage defined as absence of reinterventions for the 
management of biliary obstructive symptoms.  
â€¢ For patients undergoing surgery: from stent placement until surgery 
â€¢ For patients transitioning to palliative management: from stent placement until transition 
to palliation  
4.2.  Secondary Endpoints  
1. Occurrence and severity of adverse events related to the stent and/or stenting procedure  
2. Occurrence and severity of surgical complications  
3. Occurrence and severity of peri -surgical complications (up to 30 days after surgery)  
4. Ability to deploy the stent in satisfactory position across the stricture (Stent Placement 
Success)  
5. Improvement of biliary  obstructive symptoms  during stent indwell at Week 1 and 
Monthly until surgery or transition to palliation  as applicable, compared to Baseline  
6. Improveme nt of Laboratory Liver Function Tests (LFTs)  until surgery for patients 
undergoing surgery, and at Week 1 and Monthly until transition to palliation, and at 1 year after stent placement for patients not undergoing surgery  
7. Biliary Reintervention  rate 
8. Ability to complete neoadjuvant therapy as intended without stent related interruptions of neoadjuvant therapy 
9. Stent migration rate   
10. Assessment by surgeon of interference, if any, of SEMS on time to surgery and/or success of pancreaticoduodenectomy  
11. For patients transitioning to palliative management:  Successful biliary drainage defined as absence of reinterventions for the management of biliary obstructive symptoms from stent placement to 1 year after stent placement  
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 15 of 43 
 5.  Patient  Selection   
5.1. Inclus ion Criteria  
Patients  who meet all of the criteria  listed below  (see Table 1) may be given consideration for 
inclusion in this clinical investigation, provided no exclusion criterion (see Table 2 ) is met.  
Table 1: Inclusion Criteria  
Clinical 
Inclusion Criteria  1. Age 18 or older 
2. Patient indicated for biliary metal stent placement for the treatment of 
jaundice and/or cholestasis  
3. Willing and able to comply with the study procedures and provide written 
informed consent to participate in the study  
4. Suspicion of pancreatic adenocarcinoma  
5. Likely indicated for neoadjuvant treatment 
6. Distal biliary obstruction consistent with pancreatic cancer  
7. Location of distal biliary obstruction such that it would allow the proximal end of a stent to be positioned at least 2 cm from the hilum 
8. Endoscopic and surgical treatment to be provided at the same institution  
 
 
5.2. Exclusion Criteria  
Patients  who meet any one of the following criteria  (See Table 2)  will be excluded from this 
clinical study.  
Table 2: Exclusion Criteria  
Clinical 
Exclusion Criteria  1. Benign biliary strictures  
2. Malignancy secondary to Intraductal Papillary Mucinous Neoplasm  
3. Surgically altered anatomy where ERCP is not possible  
4. Previous biliary drainage using a SEMS or multiple plastic stents  
5. Contraindications for endoscopi c techniques  
6. Patients who are currently enrolled in another investigational trial that 
would directly interfere with the current study 
7. Pregnancy  
 
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 16 of 43 
 6.  Study Devices  
 
The WallFlex Biliary RX Fully Covered stent  and the WallFlex Biliary RX Uncovered stent  will 
be used for the treatment of patients.   The WallFlex Biliary RX Fully Covered and the WallFlex Biliary RX Uncovered Stent Systems 
are indicated for use in the palliative treatment of biliary stricture s produced by malignant 
neoplasms and relief of malignant biliary obstruction prior to surgery ; the WallFlex Biliary RX 
Fully Covered Stent System is also indicated for use in the palliative treatment of biliary  
strictures  produced by malignant neoplasms and treatment of benign biliary strictures, per CE 
Mark. For a detailed description of the WallFlex Biliary Stent Systems, please reference the Directions for Use (DFU) included in each device package.  
Investigators should use the WallFlex Biliary RX Fully Covered and Uncovered Stent Systems 
in accordance with the DFUs.  
Study devices are labeled on the box and inner pouch and contain information including but not limited to:  device name and dimensions, lot number, expirati on date, name of legal 
manufacturer, and investigational use statement. Device labeling will be provided in local language(s) as per national regulations. 
Study devices will be available in the following dimensions: 
 
WallFlex Biliary 
RX Stent  Diameter  Leng th Delivery System 
Diameter  Guidewire 
Diameter  
 Uncovered  8 mm  
10 mm  40, 60 , 80mm 
40, 60 , 80mm 8 Fr .035â€ 
 Fully Covered 8 mm  
10 mm  60, 80mm 
40, 60 , 80mm 8.5 Fr .035â€ 
 
Stent placement should be such that the proximal end of the stent is minimum 2 cm from the 
hilum.   Performing a biliary or pancreatic sphincterotomy or enlarging a prior sphincterotomy 
will be done at the discretion of the endoscopist.  Per literature, it is recommended that the shortest length of stent required to bridge the stricture
21 is used so as to leave enough of the 
normal bile duct above the stent available for subsequent anas tomosis7, 21,24,25,29.  It is hence 
anticipated that SEMS of 80 mm length will rarely or never be selected in this trial.   
 
In case of a failed stent placement due to a device event, a new attempt to place a stent will be made.  If a stent placement is not possible due to non- device related reasons (such as inability to 
cannulate the CBD or reach the papilla, extensive tumor gr owth at site of papilla, etc.), 
interventional radiologic (IR) access is allowed and, where possible, should be associated with placement of a study stent over a transhepatically inserted guide- wire in a "rendez -vous" 
E7034   Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 17 of 43 
 procedure.  Percutaneous transhepatic cholangiograp hy (PTC) and a subsequent internal drainage 
with a stent placement may be done at the same time (one-stage procedure), or PTC with 
external drainage may be performed 2 -3 days before stent insertion (two- stage procedure) per 
standard of practic e.  If access to the biliary tree or endoscopic placement of the study stent 
through a â€œrendez-vousâ€ procedure fails and patient requires percutaneous transhepatic biliary drainage (PTBD), then the patient will exit the study .  In case of failure of SEMS f unctionality 
during the neoadjuvant therapy, a new investigational SEMS may be placed, covered or uncovered at the discretion of the investigator.  In case of failure of SEMS functionality after transition to palliation, no new investigational SEMS will be  provided and patient should be 
treated per standard of practice.   
7.  Study Visits 
7.1. Visit Schedule  
The schedule of observations and assessments to take place during the study is shown in Table 3 below. 
 
  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 18 of 43 
 Table 3.  Study Event Schedule  
 
Procedure/Assessment   
 
 
 
Screening  
Baseline  Stent 
Placement  
Procedure 
Visit  Pre-Operative Follow -Up 
Visits   
 
 
Biliary 
Reintervention   
  
Curative 
Intent 
Surgery   
  
Transition to 
Palliative 
Management 
Visit   
  
Post-
Operative 
Follow -Up 
Visit  - 
30 days 
from 
surgery  
(Â±15  Days)  
Office 
Visit   
  
*Long Term 
Follow -Up Visit  
(Â± 30 Days)  
 
 Week 1  
(Â± 2 Days)  
Office 
Visit/  
Telephone 
Interview  
   
 
Monthly  
(Â±15  Days)  
Office 
Visit/  
Telephone 
Interview  
 
ICF X            
Demographics   X           
Medical history   X           
Collection of Weight   X   X  X      
Assessment of Biliary 
Obstructive Symptoms   
X   X  X  
X   
X X   
X (if applicable)  
Laboratory Liver Function Test 
(LFTs)   
X   X  X  
  
X   
X (if applicable)  
Imaginga   X           
Tumor Diagnosis, Staging, and 
Characteristics  X      
  
  
Randomization  X            
Stent Details    X     X (if applicable)  X    
Procedure Details    X     X (if applicable)      
Operative Details          X    
Specimen Pathology          X    
Planned Neoadjuvant therapy  X          
Administered Neoadjuvant 
therapy (if applicable)   
   X  X  
X  
  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 19 of 43 
 Procedure/Assessment   
 
 
 
Screening  
Baseline  Stent 
Placement  
Procedure 
Visit  Pre-Operative Follow -Up 
Visits   
 
 
Biliary 
Reintervention   
  
Curative 
Intent 
Surgery   
  
Transition to 
Palliative 
Management 
Visit   
  
Post-
Operative 
Follow -Up 
Visit  - 
30 days 
from 
surgery  
(Â±15  Days)  
Office 
Visit   
  
*Long Term 
Follow -Up Visit  
(Â± 30 Days)  
 
 Week 1  
(Â± 2 Days)  
Office 
Visit/  
Telephone 
Interview  
   
 
Monthly  
(Â±15  Days)  
Office 
Visit/  
Telephone 
Interview  
 
Surgical assessment of tumor 
invasion   
       
X  
  
Patientâ€™s overall health status   
X   X  X  
X  
X  
X 
Adverse events and 
reinterventions                X (as applicable)  
Device Events                                                                                                                          X (as applicable)  
Protocol Deviation                X (as applicable)  
 
 
a ERCP, CT and/or MRI  
 
*Long Term Follow -Up Visit: 1 year after initial treatment for patients that have transitioned to palliation or 1 year post-stent placement for patients that have not undergone 
surgery or transitioned to palliation (with or without Neoadjuvant Therapy)
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 20 of 43 
  
 
7.2. Screening  â€“ Office Visit 
â€¢ Informed Consent  
â€¢ Eligibility Criteria Assessment 
â€¢ Randomization 
 
No study- specific testing will be conducted until after the patient  has signed an Informed 
Consent Form. A Screen Failure/Enrolled Log will be maintained in EDC by the center to 
document select information about candidates who signed consent.  
Written Informed Consent must be obtained for all patients  who are potential study 
candidates.  Patients  will be ask ed to sign the Informed Consent Form before any study-
specific tests or procedures are performed.  The Informed Consent Form is study -specific and 
must be approved by the study Institutional Review Board (IRB).  Study personnel should 
explain that even if a patient  agrees to participate in the study and signs an Informed Consent 
Form, the inclusion/exclusion criteria may demonstrate that the patient  is not a suitable 
candidate for the study. Screening and enrollment information will be collected in the database for all patients who sign a consent form.  
  
7.3. Baseline Visit â€“ Office Visit  
â€¢ Demographics 
â€¢ Medical history  
â€¢ Collection of Weight 
â€¢ Patientâ€™s overall health status  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain 
o Fever/Chills  
o Jaundice 
o Itching  
o Dark urine 
o Pale stools  
o Nausea/Vomiting  
â€¢ Laboratory Liver Function Test s (LFTs)   
o Serum Albumin level 
o Total Bilirubin  
o Alkaline Phosphatase 
o SGPT (ALT)  
 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 21 of 43 
 â€¢ Imaging  
 
7.4. Tumor Diagnosis, Staging, and Characteristics â€“ Office Visit 
â€¢ Tumor Diagnosis, Staging, and Characteristics can occur any time between the 
Screening Visit and the Stent Placement Procedure Visit  
7.5. Planned Neoadjuvant Therapy  
â€¢ Planned Neoadjuvant Therapy can occur any time between the Screening Visit 
and the Stent Placement Procedure Visit  
7.6. Stent Placement Procedure Visit  â€“ Office Visit 
â€¢ Placement of WallFlex Biliary RX  stent(s)  
o During WallFlex Biliary RX  placement the stent should be adjusted with 
the proximal end of the stent no more than 1-2cm beyond the proximal end of the stricture. This favors both stability and homogeneous development of tissue hyperplasia at the proximal uncovered part.  
â€¢ Procedure Details  
â€¢ Stent Details  
â€¢ Adverse Events  (as applicable)  
â€¢ Device Events (as applicable)  
7.7. Pre-Operative Follow- Up Visit â€“ Phone and/ or Office Visit  
â€¢ Week 1 and Monthly until surgery or transition to palliation  as applicable  
â€¢ Collection of Weight 
â€¢ Patientâ€™s overall health status   
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain 
o Fever/Chills  
o Jaundice 
o Itching  
o Dark urine 
o Pale stools  
o Nausea/Vomiting  
â€¢ Laboratory Liver Function Tests (LFTs)   
o Serum Albumin level 
o Total Bilirubin  
o Alkaline Phosphatase 
o SGPT (ALT)  
 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 22 of 43 
 â€¢ Administered Neoadjuvant therapy 
â€¢ Adverse event s and reinterventions (as applicable)  
â€¢ Device Events (as applicable)  
7.8. Biliary Reintervention Visit (Arm 1 or 2) â€“ as needed  
â€¢ Timing  
â€¢ Reason for Biliary Reintervention 
â€¢ Type of Biliary Reintervention (including SEMS placement or removal)  
â€¢ Adverse Events (as applicable)  
â€¢ Device Events (as applicable)  
7.9. Curative Intent Surgery â€“ Office Visit 
â€¢ Patientâ€™s overall health status  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain 
o Fever/Chills  
o Jaundice 
o Itching  
o Dark urine 
o Pale stools  
o Nausea/Vomiting  
â€¢ Operative Details  
â€¢ Stent Removal  
â€¢ Surgical Complications including intraoperative blood loss 
â€¢ Intra - and Post-Operative Transfusion 
â€¢ Post-Operative Course 
â€¢ Specimen Pathology 
â€¢ Administered Neoadjuvant therapy 
â€¢ Adverse event s and reinterventions (as applicable)  
â€¢ Device Events (as applicable)  
7.10. Transition to Palliative Management Visit (as needed)  â€“ Phone and/ or Office 
Visit 
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain 
o Fever/Chills  
o Jaundice 
o Itching  
o Dark urine 
o Pale stools  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 23 of 43 
 o Nausea/Vomiting  
â€¢ Laboratory Liver Function Tests (LFTs)  
o Serum Albumin level 
o Total Bilirubin  
o Alkaline Phosphatase 
o SGPT (ALT)  
â€¢ Adverse Events  (as applicable)  
â€¢ Device Events (as applicable)  
7.11. Post-Operative Follow- Up Visit (30 days) â€“ Phone and/or  Office Visit 
â€¢ Day 30 Post-Surgery Visit  
â€¢ Patientâ€™s overall  health status  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain 
o Fever/Chills  
o Jaundice 
o Itching  
o Dark urine 
o Pale stools  
o Nausea/Vomiting  
â€¢ Adverse event s and reinterventions (as applicable)  
â€¢ Device Events (as applicable)  
 
7.12.   Long Term Follow -Up Visit ( 1 year after initial tr eatment  for patients that 
have transitioned to palliation or 1 year post- stent placement for patients that 
have not undergone surgery or transitioned to palliation ( with or without 
Neoadjuvant Therapy) â€“ Phone and/ or Office Visit 
â€¢ For patients not undergoing surgery 
â€¢ Patientâ€™s overall health status  
â€¢ Assessment of Biliary Obstructive Symptoms  
o Right Upper Quadrant Pain 
o Fever/Chills  
o Jaundice 
o Itching  
o Dark urine 
o Pale stools  
o Nausea/Vomiting  
â€¢ Laboratory Liver Function Tests (LFTs)  
o Serum Albumin level 
o Total Bilirubin  
o Alkaline Phosphatase 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 24 of 43 
 o SGPT (ALT)  
 
â€¢ Adverse event s and reinterventions (as applicable)  
â€¢ Device Events (as applicable)  
 
  7.13.    Study Completion 
End of study will be reached at: 
â€¢ Up to 30 days post-surgery for those patients undergoing potential curative intent 
surgery 
â€¢ 1 year  post stent placement for patients that have transitioned to palliation within 12 
months after stent placement  
â€¢ 1 year  post stent placement for patients who do not undergo potential curative intent 
surgery and do not transition to palli ation  within 12 months after stent placement 
(with or without Neoadjuvant Therapy) 
End of study will be reached at study completion, at patient withdrawal from study, or at death , whichever comes first.   
8.  Statistical Considerations  
8.1  Hypotheses  
Compared to the use of an Uncovered SEMS, use of a Fully Covered SEMS may present a higher risk of migration, but offers the ability to remove the stent were this deemed indicated by the treating endoscopist.  Statistical testing will be performed to deter mine if the rate of 
success when using the Fully Covered SEMS is non- inferior to the rate of success when 
using the Uncovered  SEMS.  The following hypothesi s will be tested: 
 
ð»ð»ð»ð»: ðœ‹ðœ‹ð‘ˆð‘ˆð‘ˆð‘ˆâˆ’ðœ‹ðœ‹ð¹ð¹ð‘ˆð‘ˆ â‰¥ âˆ†  (Inferior) 
ð»ð»ð»ð»: ðœ‹ðœ‹ð‘ˆð‘ˆð‘ˆð‘ˆâˆ’ðœ‹ðœ‹ð¹ð¹ð‘ˆð‘ˆ <âˆ†  (Non-inferior) 
 
w
here ðœ‹ðœ‹ð¹ð¹ð‘ˆð‘ˆ  and ðœ‹ðœ‹ð‘ˆð‘ˆð‘ˆð‘ˆ are the probabilities of having success in the WallFlex Fully Covered 
Stent and WallFlex Uncovered Stent arms respectively, and âˆ† is defined as the non-
inferiority margin.  
8.2
 Sample Size  
The sample size was calculated for the test using an exact non- inferiority  test in StatXact 9Â® 
software. The non- inferiority margin (Î”) is  set at 20%. Each arm  is assumed to have a 
success rate of 8 0.5%, which is the lower 95% CI boundary from the meta- analysis , which is 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 25 of 43 
 done below. Given thes e assumptions  a sample size of  51 x 2 = 102 patients provides 80% 
power to reject the null hypothesis listed above. If the p- value calculated for the test is below 
0.05 it will be concluded that the test is significant and that the WallFlex Fully Covered s tent 
is non- inferior to the WallFlex Uncovered stent .   
 
In order to compensate for possible loss of patients  to follow-up or per Endoscopistâ€™s 
decision to select the Uncovered stent based on ductal anatomy, namely stricture involving the low cystic duct confluence, an additional 20% of patients  will be enrolled giving a total 
sample size of 122 patients . 
The suc cess rate estimate is extracted from a full literature search which yielded nine articles 
(377 patients ) 
2, 7, 21, 24, 25, 27, 29 -31 on the use metal stents for pre -operative biliary drainage.  
The nine articles yielded a success rate estimate of 8 4.6% wit h a 95% CI of (80.5%, 87.9%).  
8.3 Analysis Populations  
8.3.1   Enrolled Cohort  
A patient  is considered â€œenrolledâ€ after signing the study- specific ICF.  Patients  who sign the 
ICF but subsequently do not meet one or more of the eligibility criteria provided in Section 5.1 and Section 5.2 will be considered screen failures and excluded from the study. 
8.3.2. Intent -to-Treat Cohort  
This cohort consists of those â€œenrolledâ€ patient s who meet all inclusion/exclusion criteria  and 
are subsequently randomized. 
8.3.3.   Per-Protocol Cohort The per -protocol cohort is a subset of the ITT patients  who are treated per protocol and have 
no major protocol deviations (per ICH E9 definitions). 
8.4 Data Analysis 
All statistical analyses will be done using The SAS System software, version 8 or higher 
(Copyright Â© 2000 SAS Institute Inc., SAS Campus Drive, Cary, North Carolina 27513, USA. All rights reserved).   The distribution of prognostic factors be tween patients with and without data will be 
examined. Statistical models that account for censored data will be employed in appropriate circumstances, e.g. for time- to-event outcomes. Sensitivity analyses will be conducted to 
assess the impact of missing data on the interpretation of the results, e.g. a tipping point analysis.  
 8.4.1.  Baseline Data  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 26 of 43 
 Patient  demographics, clinical history, risk factors, obstructive symptoms, LFTs, tumor 
diagnosis, patient  overall health, neoadjuvant therapy, and assessment of tumor invasion will 
be summarized using descriptive statistics (e.g., mean, standard deviation, n, minimum, 
maximum) for continuous variables and frequency tables for discrete variables.    8.4.2.  Post Procedure Data  Post-procedure information will be collected at regularly scheduled follow-up examinations as detailed in the clinical study event schedule and will be summarized using descriptive statistics for continuous variables (e.g., mean, standard deviation, n, minimum, maximum) and frequency tables or proportions for discrete variables.  
 
8.4.3.  Interim Analyses  
 No formal interim analyses are planned for this study. 
 
8.4.4.  Subgroup Analyses  
 Stratified  analyses will include tabulating the primary endpoint and sele ct secondary 
endpoints by patients that undergo potentially curative surgery  versus transition to palliation, 
by bilirubin level above or below 3 mg/dL , and gender .  
 8.4.5.  Justification of Pooling  The analyses will be performed using data pooled across institutions. An assessment of the poolability of patients  across sites will be made by fitting generalized linear models with site 
as the factor of interest and the primary endpoint as the outcome.  
 8.4.6.  Multivariable Analyses  Univariate and multivariate analyses may be performed to assess the effect of potential predictors on the primary endpoint using logistic regression or Cox Proportional Hazards regression.  
Variables from the follow ing categories will be considered as possible predictors: 
demographics, tumor diagnosis, baseline LFTs, neoadjuvant therapy protocol, obstructive 
symptoms, baseline health status, and medical history. Factors from the univariate model with pâ‰¤0.20 will also be modeled multivariately using a stepwise procedure in a generalized linear model or Cox Proportional Hazards regression model. The significance thresholds for entry and exit into the model will be set to pâ‰¤0.10.  8.4.7.  Changes to Planned Analyses  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 27 of 43 
 Any changes to the planned statistical analyses made prior will be documented in an 
amended Statistical Analysis Plan.  
9.   Potential Risks and Benefits  
 
9.1.  Anticipated Adverse Device Effects  
 
The following anticipated adverse device effects (ADE)  should be reported only if they are 
related to the stent and/or stenting procedure.  They have been identified for the WallFlex 
Biliary FC and UC Stent, as indicated in the commercial Directions for Use (DFU) and may include, but are not limited to:   
â€¢ Pain 
â€¢ Bleeding  
â€¢ Fever  
â€¢ Nausea  
â€¢ Vomiting  
â€¢ Infection  
â€¢ Inflammation  
â€¢ Recurrent obstructive jaundice  
â€¢ Stent occlusion 
â€¢ Tumor overgrowth around ends of stent 
â€¢ Tumor ingrowth through the stent 
â€¢ Mucosal hyperplasia  
â€¢ Cholangitis  
â€¢ Cholecystitis  
â€¢ Pancreatitis  
â€¢ Ulceration of duodenum or bile duct 
â€¢ Perforation of duodenum or bile duct 
â€¢ Stent migration  
â€¢ Death (other than that due to normal disease progression) 
â€¢ Stent misplacement 
â€¢ Perforation of the gallbladder due to the stent covering the cystic duct 
â€¢ Stent Fracture  
â€¢ Hepatic abscess  
 
9.2.   Anticipated Surgical Adverse Events  
â€¢ Pancreaticojejunostomy leakage  
â€¢ Hepaticojejunostomy leakage  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 28 of 43 
 â€¢ Gastro -duodenojejunostomy leakage  
â€¢ Delayed gastric emptying   
â€¢ Biliary leakage  
â€¢ Intra -abdominal abscess formation  
â€¢ Wound infection  
â€¢ Portal Vein Thrombosis  
â€¢ Cholangitis   
â€¢ Hemorrhage  
â€¢ (Emergency) (re)laparotomy   
â€¢ Pneumonia 
â€¢ Myocardial infarction  
â€¢ Mortality  
9.3.   Risk Minimization Actions  
Additional risks may exist. Risks can be minimized by performing procedures in the 
appropriate hospital environment, adher ing to patient  selection criteria, and close monitoring 
the patient 's physiologic status during research procedures and/or follow- up visits.   Promptly 
supplying BSC with all pertinent information required by this protocol may facilitate inter -
center communications regarding serious AEs. 
9.4.  Anticipated Benefits  
Patients  may not receive any benefit from participating in this study but this study may 
provide a future benefit to medical science and other patients.  To date there is no broadly accepted standard of practice pertaining to the use of SEMS for Pre -operative management of 
patients with pancreatic cancer undergoing neoadjuvant therapy. 
9.5.  Risk to Benefit Rationale 
Based on prior BSCâ€™s clinical studies and collected reports in literature to -date, the risk -to-
benefit ratio is within reason for foreseeable risks. However, literature reports do not always capture all side effects. Observation and follow up of patients  is required as outlined in the 
protocol. 
10.  Safety Reporting  
 
10.1.  Definitions and Classification  
Adverse event definitions are provided in Table 4 .  
 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 29 of 43 
 Table 4: Adverse Event Definitions  
Term  Definition  
Adverse Event (AE)  
 
Ref: ISO 14155 -2011  
 
  Any untoward medical occurrence, unintended disease or injury, or any 
untoward clinical signs (including an abnormal laboratory finding) in 
patients , users or other persons, whether or not related to the 
investigational medical device. This includes events related to: 
â€¢ The investigational medical device or comparator 
â€¢ The procedures involved (study- required)  
 
For users/other persons, this definition is restricted to events related to the 
investigational device  
  
Adverse Device Effect (ADE)  
 Ref: ISO 14155 -2011  
  Adverse event related to the use of an investigational medical device: 
â€¢ This includes adverse events resulting from insufficient or inadequate instructions for the use, deployment, implantation, 
installation or operation, or any malfunction of the investigational medical device.  
â€¢ This includes any event resulting from use error or from intentional misuse of the investigational medical device.  
 
Serious Adverse Event (SAE)  
 
Ref: ISO 14155 -2011  
 
 Adverse event that:  
â€¢ Led to death, 
â€¢ Led to  serious deterioration in the health of the patient, that either 
resulted in:  
o a life -threatening illness or injury, or  
o a permanent impairment of a body structure or  a body function, or  
o in-patient hospitalization   or prolonged hospitalization ( of existing 
hospitalization ), or 
o medical or surgical intervention to prevent life -threatening illness or 
injury or permanent impairment to a body structure or a body function  
â€¢ Led to fetal distress, fetal death, or a congenital abnormality or birth defect.  
Note : Planned hospitalization for a pre -existing condition, or a procedure 
required by the protocol , without serious deterioration in health, is not 
considered a serious adverse event.  
Note:  For SAE reporting requirements see the information below for SADE.  
Serious Adverse Device Effect (SADE)  
 
Ref: ISO 14155 -2011  
 
 Adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event.  
Note:  All SAEs that could have led to a SADE if suitable action had not been taken or if circumstances had been less fortunate shall be reported as required by the local IRB/EC, national regulations, or the protocol.  If 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 30 of 43 
 Table 4: Adverse Event Definitions  
Term  Definition  
applicable, see MEDDEV 2.7/3  12/2010 for reporting timeline 
requirements.  
Unanticipated Adverse Device 
Effect (UADE) 
 
Ref: 21 CFR Part 812  
 Any serious adverse effect on health or safety or any life -threatening 
problem or death caused by, or associated with, a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence in the investigatio nal plan or application (including a 
supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.   
Unanticipated Serious Adverse Device Effect (USADE)  
 
Ref: ISO 14155 -2011  
 
 
 Serious adverse device effect which by its nature, incidence, severity, or outcome has not been identified in the current version of the risk analysis report.  
Note: Anticipated serious adverse device effect (ASADE) is an effect 
which by its nature, incidence, severity or outcome has been identified in the risk analysis report.  
Device Deficiency  
 
Ref: ISO 14155 -2011  
 
Ref: MEDDEV 2.7/3 12/2010  A device deficiency is any inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance.  
Note: Device deficiencies include malfunctions, misuse or use errors, and 
inadequate labeling.  
Note: All device deficiencies that could  have led to a SADE if suitable 
action had not been taken or if circumstances had been less fortunate shall be reported as required by the local IRB/EC, national regulations, or the 
protocol.  If applicable, see MEDDEV 2.7/3 12/2010 for reporting 
timeline requirements.  
Abbreviations: EC=Ethics Committee; IRB=Institutional Review Board  
 
Underlying diseases are not reported as AEs unless there is an increase in severity or 
frequency during the course of the investigation. Death should not be recorded as an AE, but should only be reflected as an outcome of a specific SAE (see Table 4  for AE  definitions).  
All device -related events and all surgery related events  experienced by the study patient  after 
informed consent, whether during or subsequent to the procedure, must be recorded in the eCRF.  
10.2.  Relationship to Study Device(s)  
The Invest igator must assess the relationship of the AE to the study device as related or 
unrelated. Unrelated AEs will not be reported.  Per protocol, only complications related to stent and/or stenting procedures will be reported.  See criteria in Table 5 .   
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 31 of 43 
 Table 5: Criteria for Assessing Relationship of Study Device to Adverse Event  
Classification  Description  
Unrelated  The adverse event is determined to be due to a concurrent illness or effect of 
another device and is not related to the investigational product.  
Related  â€¢ The adverse event is determined to be potentially related to the investigational 
product, and an alternative etiology is equally or less likely compared to the potential relationship to investigational product. 
â€¢ There is a strong relationship to investigational product, or recurs on re -
challenge, and another etiology is unlikely. 
â€¢ There is no other reasonable medical explanation for the event.  
10.3.  Investigator Reporting Requirements 
Investigators will be required to report all SAEs and ADEs.  
10.3.1.  Serious Adverse Events 
 These events should be reported to the Sponsor within 2 business days of first becoming aware of the event.  Events should be documented in the eCRF and all relevant source documentation for the event should be provided to the Safety Trial Manager, as applicable.  
10.3.2.  Adverse Events  Device-related events should be reported to the Sponsor within 10 business days of first becoming aware of the event.  Unrelated AEs will not be collected.  
10.3.3.  Device Failures, Malfunctions, and Product Nonconformities  
 These events should be reported to the Sponsor within 1 business day of first becoming aware of the event.  Events should be documented in the eCRF. 
10.4.  Boston Scientific Device Deficiencies  
All device deficiencies (including but not limited to failures, malfunctions, use errors, product nonconformities, and labeling errors) will be documented and reported to BSC. If possible, the device(s) should be returned to BSC for analysis. Instructions for returning the investigational device(s) will be provided. If it is not possible to return the device, the investigator should document why the device was not returned and the final disposition of the device. Device failures and malfunctions should also be documented in the patientâ€™s medical record.  
Device deficiencies, failures, malfunctions, and product nonconformities are not to be reported as adverse events. However, if there is an adverse event that results from a device failure or malfunction, that specific event would be recorded on the appropriate eCRF.  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 32 of 43 
 10.5.  Reporting to Regulatory Authorities / IRBs / Investigators  
BSC is responsible for reporting adverse event information to all participating investigators 
and regulatory authorities, as applic able.  
The Principal Investigator is responsible for informing the IRB and regulatory authorities of SAEs as required by local procedure.   
11.  Bibliography  
 
1. Bonin E, Baron T.  Preoperative biliary stents in pancreatic cancer.  J Hepaticobiliary 
Pancreat Sci 2011;18:621-629 
2. Adams M, Anderson M, Myles J, et al.  Self -expanding metal stents (SEMS) provide superior 
outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant 
therapy.  J Gastrointest Oncol 2012;3(4):309 -313. 
3. The Wo rld Health Organization.  â€œGlobal cancer rates could increase by 50% to 15 million 
by 2020â€.  3 Apr. 2003.  http://www.who.int/mediacentre/news/releases/2003/pr27/en/ 
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ.  Cancer statistics, 2007. CA Cancer J 
Clin 2007;57:43-66. 
5. Dumonceau J, DeviÃ¨re J.   Self -expandable metal stents . BailliÃ¨reâ€™s Clinical Gastroenterology. 
1999; 1:109-130. 
6. Boulay BR, Gardner TB, Gordon SR.  Occlusion rate and complications of plastic biliary stent placement in patients undergoing neoadjuvant chemoradiotherapy for pancreatic 
cancer with malignant biliary obstruction.  J Clin Gastroenterol 2010 Jul;44(6):452-5 
7. Singal AK, Ross WA, Guturu P, et al.  Self -Expanding Metal Stents for Biliary Drainage in 
Patients with Resectable Pancreatic Cancer: Single- Center Experience with 79 Cases.   Dig 
Dis Sci 2011 Jul 13. [Epub ahead of print] 
8. Katz MH, Want H, Fleming JB, et al. Long- term survival after multidisciplinary management 
of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009 Apr;16(4):836-47. 
9. Lowy AM. Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg. 2008;12:1600â€“1608. 
10. Evans DB, Wolff RA, Crane CH. Neoadjuvant strategies for pancreatic cancer . Oncology 
(Williston Park). 2001;15:727â€“737. 
11. Greer SE, Pipas JM, Sutton JE, et al. Effect of neoadjuvant therapy on local recurrence after 
resection of pancreatic adenocarcinoma. J Am Coll Surg. 2008;206:451â€“457. 
12. NCCN, Guideline: Pancreatic Adenocarcinoma, 2012 
13. Wolff R.  Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas. Curr Drug Targets. 2012 Jun;13(6):781-8 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 33 of 43 
 14. Breslin T, Hess K, Harbison D, et al.  Neoadjuvant chemoradiotherapy for adenocarcinoma 
of the pancreas: treatment variables and survival duration.  Ann  Surg Oncol. 2001 Mar;8(2): 
123-32 
15. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605 â€“1617. 
16. Feig BW, Berger DH, Fuhrman GM.   The M.D. Anderson surgical oncology handbook .    
Lippincott Williams & Wilkins, 2006 
17. Das A, Sivak MV.   Endoscopic palliation for inoperable pancreatic cancer.  Cancer Control 
2000 Sep/Oct; 7(5): 452-457 
18. Garcea G, Chee W, Ong SL, et al. Preoperative biliary drainage for distal obstruction the case against revisited . Pancreas 2010;39:119â€“126.  
19. Coates JM, Beal SH, Russo JE, et al. Negligible effect of selective preoperative biliary 
drainage on perioperative resuscitation, morbidity, and mortality in patients undergoing pancreaticoduodenectomy . Arch Surg 2009;144:841â€“847.  
20. Jaganmohan S, Lee J.  Self -expandable metal stents in malignant biliary obstruction.  Expert 
Rev.  Gastroenterol Hepatol 2012. 6(1), 105-114 
21. Aadam AA, Evans DB, Khan A, et al.  Efficacy and safety of self -expandable metal stents for 
biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a 
prospective study, Gastrointest Endosc 2012 Jul;76 (1) :67-75.  Epub 2012 Apr 5. 
22. Lacaine F, Fourtanier G, Fingerut A, et al. Surgical mortality and morbidity in malignant 
obstructive jaundice: a review of 373 patients. Eur J Surg 1995;161:729 â€“734.  
23. Armstrong CP, Dixon JM, Taylor V, et al. Surgical experience of deeply jaundiced patients with bile duct obstruction. Br J Surg 1984;71:234â€“238.  
24. Wasan SM, Ross WA, Staerkel GA, Lee GH.  Use of Expandable Metallic Biliary Stents in 
Resectable Pancreatic Cancer. Am J Gastroenterol. 2005;100:2056â€“2061 
25. Mullen JT, Lee JH, Gomez HF, Ross WA, et al.  Pancreaticoduodenectomy After Placement of Endobiliary Metal Stents.  J Gastrointest Surg 2005;9:1094â€“1105 
26. van der Gaag NA, Rauws EAJ, van Eijck CHJ, et al.  Preoperative Biliary Drainage for 
Cancer of the Head of the Pancreas.   N Engl J Med 2010;362:129-37 
27. Decker C, Christein JD, Phadnis MA et al.   Biliary metal stents are superior to plastic stents for preoperative biliary decompression in pancreatic cancer.  Surg Endosc 2011 
Jul;25(7):2364-7. Epub 2011 Mar 4 
28. Sanders Mk, El Hajj II, Slivka A, et al.  Placement of Self Expanding Metal Biliary   
Stents (SEMS) in Patients with Resectable Pancreatic Cancer [Abstract].  Gastrointest Endosc 2009; 69 (5) 
29. Kahaleh M, Brock A, Conaway MR, et al. Covered selfâˆ’expandable metal stents in 
pancreatic malignancy regardless of resectability: a new concept validated by a decision 
analysis.  Endoscopy 2007 Apr;39(4):319-24 
30. Pop GH, Richter JA, Sauer B, et al. Bridge to  surgery using partially covered self -expandable 
metal stents (PCMS) in malignant biliary stricture: an acceptable paradigm?  Surg Endosc 
2011 Feb;25(2):613-8 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 34 of 43 
 31. Lawrence C, Howell DA, Conklin DE, et al. Delayed pancreaticoduodenectomy for cancer 
patients wit h prior ERCP- placed, nonforeshortening, self -expanding metal stents: a positive 
outcome , Gastrointest Endosc 2006 May;63 (6): 804-807 
32. Cavell L, Allen P, Vinoya C, et al.  Biliary Self -Expandable Metal Stents Do Not Adversely 
Affect Pancreaticoduodenectomy .  Am J Gastroenterol 2013 April; doi: 10.1038/ajg.2013.93  
33. Mezhir, J., et al.  A matched case-control study of preoperative biliary drainage in patients 
with pancreatic adenocarcinoma: routine drainage is not justified.  J Gastrointest Surg, 2009. 
13(12): p. 2163-9 
34. Heslin, M., et al.  A preoperative biliary stent is associated with increased complications 
after pancreaticoduodenectomy.  Arch Surg, 1998. 133(2): p. 149-54. 
35. Povoski, S., et al.  Preoperative biliary drainage: impact on intraoperative bile cult ures and 
infectious morbidity and mortality after pancreaticoduodenectomy.  J Gastrointest Surg, 
1999. 3(5): p. 496-505.  
36. Son, J., et al.  The optimal duration of preoperative biliary drainage for periampullary 
tumors that cause severe obstructive jaundice.  AM J Surg, 2013.  206, 40-46 
APPENDIX B : SPONSOR REQUIRED PROTOCOL SECTIONS  
B.1.  Data Management  
 
B.1.1.  Data Collection, Processing, and Review  
 
Patient  data will be recorded in a limited access secure electronic data capture (EDC) system.  
The clinical database will reside on a production server. All changes made to the clinical data 
will be captured in an electronic audit trail and available for review by Boston Scientific Corporation (BSC) or its representative. The associated software and dat abase have been 
designed to meet regulatory compliance for deployment as part of a validated system compliant with laws and regulations applicable to the conduct of clinical studies pertaining to the use of electronic records and signatures. Database backu ps are performed regularly.  
The Investigator provides his/her electronic signature on the appropriate electronic case report forms (eCRFs) in compliance with local regulations. A written signature on printouts of the eCRFs must also be provided if required by local regulation. Changes to data previously submitted to the sponsor require a new electronic signature by the Investigator acknowledging and approving the changes. 
Visual and/or electronic data review will be performed to identify possible data 
discrepancies. Manual and/or automatic queries will be created in the EDC system and will be issued to the site for appropriate response. Site staff will be responsible for resolving all queries in the database.  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 35 of 43 
  
B.1.2.  Data Retention  
 
The Investigator will maintain, at the investigative site, in original format all essential study 
documents and source documentation that support the data collected on the study patients  in 
compliance with ICH/GCP guidelines.  Documents must be retained for at least 2 years after  
the last approval of a marketing application or until at least 2 years have elapsed since the formal discontinuation of the clinical investigation of the product. These documents will be retained for a longer period of time by agreement with BSC or in com pliance with other local 
regulations. It is BSCâ€™s responsibility to inform the Investigator when these documents no longer need to be maintained. The Investigator will take measures to ensure that these essential documents are not accidentally damaged or destroyed. If for any reason the Investigator withdraws responsibility for maintaining these essential documents, custody must be transferred to an individual who will assume responsibility and BSC must receive written notification of this custodial change.   
B.2.  Amendments  
 
If a protocol revision is necessary which affects the rights, safety or welfare of the patient  or 
scientific integrity of the data, an amendment is required. Appropriate approvals (e.g., IRB/ EC/ FDA /CA) of the revised protocol must be obtained prior to implementation.  
B.3.   Device/Equipment Accountability  
 There are no investigational devices used in this study. The WallFlex Biliary Fully Covered and Uncovered Stent Systems are available for commercial use in the geographic areas in which this clinical study is taking place; therefore, there is no requiremen t for device 
accountability for the purposes of this study. Device lot information must be maintained in the subjectâ€™s medical record and recorded on the appropriate case report form.   Any individual country/region requirements that depart from the aforementioned will be implemented on a case- by-case basis.  
B.4.  Deviations 
 
An Investigator must not make any changes or deviate from this protocol, except to protect the life and physical well -being of a patient  in an emergency. An investigator shall notify the 
sponsor and the reviewing IRB /EC of any deviation from the investigational plan to protect 
the life or physical well-being of a patient  in an emergency, and those deviations which affect 
the scientific integrity of the clinical investigation. Such  notice shall be given as soon as 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 36 of 43 
 possible, but no later than 5 working days after the emergency occurred, or per prevailing 
local requirements, if sooner than 5 working days.  
All deviations from the investigational plan, with the reason for the deviation and the date of 
occurrence, must be documented and reported to the sponsor using the Protocol Deviation EDC CRF.  Sites may also be required to report deviations to the IRB /EC, per local 
guidelines and government regulations. 
Deviations will be reviewed an d evaluated on an ongoing basis and, as necessary, appropriate 
corrective and preventive actions (including notification, center re- training, or 
discontinuation) will be put into place by the sponsor. 
B.5.  Compliance  
 
B.5.1.  Statement of Compliance 
 This study will be conducted in accordance with FDA regulations, ISO 14155: Clinical 
Investigation of Medical Devices for Human Subjects  â€“ Good Clinical Practices,  the relevant 
parts of the ICH Guidelines for Good Clinical Practices,  ethical principles that have their 
origins in the Declaration of Helsinki, and pertinent individual country laws and regulations. The study shall not begin until the required approval/favorable opinion from the IRB /EC 
and/or regulatory authority has been obtained, if appropriate. Any additional requirements 
imposed by the IRB /EC shall be followed, if appropriate. 
 B.5.2.  Investigator Responsibilities  The Principal Investigator of an investigational center is responsible for ensuring that the study is conducted in accordance with the Clinical Study Agreement, the investigational plan/protocol, ISO 14155, ethical principles that have their origins in the Declaration of Helsinki, any conditions of approval imposed by the reviewing IRB /EC, and prevailing loca l 
and/or country laws and/or regulations, whichever affords the greater protection to the patient . 
The Principal Investigatorâ€™s responsibilities include, but are not limited to, the following.  
â€¢ Prior to beginning the study, sign the Investigator Agreement and Protocol Signature 
page documenting his/her agreement to conduct the study in accordance with the protocol. 
â€¢ Provide his/her qualifications and experience to assume responsibility for the proper conduct of the study and that of key members of the center team through up- to-date 
curriculum vitae or other relevant documentation and disclose potential conflicts of interest, including financial, that may interfere with the conduct of the clinical study or interpretation of results.  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 37 of 43 
 â€¢ Make no changes in or deviate from this protocol, except to protect the life and physical 
well-being of a patient  in an emergency; document and explain any deviation from the 
approved protocol that occurred during the course of the clinical investigation. 
â€¢ Create and maintain source documents throughout the clinical study and ensure their availability with direct access during monitoring visits or audits; ensure that all clinical-investigation -related records are retained per requirements.  
â€¢ Ensure the accuracy, completeness, legibility , and timeliness of the data reported to the 
sponsor in the CRFs and in all required reports. 
â€¢ Record, report, and assess (seriousness and relationship to the device/procedure) every 
adverse event and observed device deficiency.  
â€¢ Report to BSC, per the protocol requirements, all SAEs and device deficiencies that 
could have led to a SADE. 
â€¢ Report to the IRB/EC and regulatory authorities any SAEs and device deficiencies that could have led to a SADE, if required by the national regulations or this protocol or by the IRB/EC, and supply BSC with any additional requested information related to the safety reporting of a particular event.  
â€¢ Maintain the device accountability records and control of the device, ensuring that the investigational device is used only by authorized/designated users and in accordance with this protocol and instructions/directions for use. 
â€¢ Allow the sponsor to perform monitoring and auditing activities, and be accessible to the monitor and respond to questions during monitoring visits. 
â€¢ Allow and  support regulatory authorities and the IRB /EC when performing auditing 
activities.  
â€¢ Ensure that informed consent is obtained in accordance with this protocol and local 
IRB/EC requirements.  
â€¢ Provide adequate medical care to a patient  during and after a patie ntâ€™s participation in a 
clinical study in the case of adverse events, as described in the Informed Consent Form 
(ICF).  
â€¢ Inform the patient  of the nature and possible cause of any adverse events experienced. 
â€¢ As applicable, provide the patient  with necessary instructions on proper use, handling, 
storage, and return of the investigational device when it is used/operated by the patient . 
â€¢ Inform the patient  of any new significant findings occurring during the clinical 
investigation, including the need for additional medical care that may be required.  
â€¢ Provide the patient  with well-defined procedures for possible emergency situations 
related to the clinical study, and make the necessary arrangements for emergency 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 38 of 43 
 treatment, including decoding procedures for blinded/m asked clinical investigations, as 
needed.  
â€¢ Ensure that clinical medical records are clearly marked to indicate that the patient  is 
enrolled in this clinical study.  
â€¢ Ensure that, if appropriate, patients  enrolled in the clinical investigation are provided with 
some means of showing their participation in the clinical investigation, together with 
identification and compliance information for concomitant treatment measures (contact address and telephone numbers shall be provided). 
â€¢ Inform, with the patient â€™s approval or when required by national regulations, the patient â€™s 
personal physician about the patient â€™s participation in the clinical investigation.  
â€¢ Make all reasonable efforts to ascertain the reason(s) for a patientâ€™s premature withdrawal 
from clinical investigation while fully respecting the patient â€™s rights.  
â€¢ Ensure that an adequate investigation site team and facilities exist and are maintained and 
documented during the clinical investigation. 
â€¢ Ensure that maintenance and calibration of the equipment relevant for the assessment of the clinical investigation is appropriately performed and documented, where applicable. 
 B.5.3.  Delegation of Responsibility  When specific tasks are delegated by an investigator, including but not limited to conducting the informed consent process, the investigator is responsible for providing appropriate training and adequate supervision of those to whom tasks are delegated. The investigator is accountable for regulatory violations resulting from failure to adequately supervise the conduct of the clinical study.  
B.6.  Institutional Review Board/Ethics Committee  
 Prior to gaining Approval- to-Enroll status, the investigational center will provide to the 
sponsor documentation verifying that their IRB is registered or that registration has been submitted to the appropriate agency, as applicable according to national/regulatory requirements.   
A copy of the written IRB/EC and/or competent authority approval of the protocol (or 
permission to conduct the study) and Informed Consent Form, must be received by the sponsor before recruitment of patients  into the study and shi pment of investigational 
product/equipment. Prior approval must also be obtained for other materials related to patient  
recruitment or which will be provided to the patient . 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 39 of 43 
 Annual IRB /EC approval and renewals will be obtained throughout the duration of the study 
as required by local/country or IRB /EC requirements. Copies of the Investigatorâ€™s reports 
and the IRB/EC continuance of approval must be provided to the sponsor.  
B.7.  Monitoring  
 
Monitoring will be performed during the study to assess continued c ompliance with the 
protocol and applicable regulations. In addition, the monitor verifies that study records are adequately maintained, that data are reported in a satisfactory manner with respect to timeliness, adequacy, and accuracy, and that the Investigator continues to have sufficient staff and facilities to conduct the study safely and effectively. The Investigator/institution guarantees direct access to original source documents by BSC personnel, their designees, and appropriate regulatory authoritie s. 
The study may also be subject to a quality assurance audit by BSC or its designees, as well as inspection by appropriate regulatory authorities. It is important that the Investigator and relevant study personnel are available during on -site monitoring visits or audits and that 
sufficient time is devoted to the process.  
B.8.  Insurance  
 Where required by local/country regulation, proof, and type of insurance coverage, by BSC for patients  in the study will be obtained. 
B.9.  Informed Consent  
 Patient  participation in this clinical study is voluntary.  Informed Consent is required from all 
patients  or their legally authorized representative. The Investigator is responsible for ensuring 
that Informed Consent is obtained prior to the use of any investigational devices, study-required procedures and/or testing, or data collection.  
The obtaining and documentation of Informed Consent must be in accordance with the 
principles of the Declaration of Helsinki, ISO 14155, any applicable national regulations, and local Ethics Committee and/or Regulatory authority body, as applicable. The ICF must be approved by the centerâ€™s IRB /EC, or central IRB, if applicable.  
Boston Scie ntific will provide a study -specific template of the ICF to investigators 
participating in this study. The ICF template may be modified to meet the requirements of the investigative centerâ€™s IRB /EC.  Any modification requires approval from BSC prior to use of 
the form.  The ICF must be in a language understandable to the patient  and if needed, BSC 
will assist the center in obtaining a written consent translation. Translated consent forms 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 40 of 43 
 must also have IRB /EC approval prior to their use.  Privacy language shall be included in the 
body of the form or as a separate form as applicable.   
The process of obtaining Informed Consent shall: 
â€¢ be conducted by the Principal Investigator or designee authorized to conduct the process,  
â€¢ include a description of all aspects of the clinical study that are relevant to the patient â€™s 
decision to participate throughout the clinical study, 
â€¢ avoid any coercion of or undue influence of patients  to participate,  
â€¢ not waive or appear to waive patient â€™s legal rights,  
â€¢ use native language t hat is non-technical and understandable to the patient  or his/her legal 
representative,  
â€¢ provide ample time for the patient  to consider participation and ask questions if 
necessary,  
â€¢ ensure important new information is provided to new and existing patients  throughout the 
clinical study.  
The ICF shall always be signed and personally dated by the patient  or legal representative 
and by the investigator or an authorized designee responsible for conducting the informed 
consent process. If a legal representative si gns, the patient  shall be asked to provide informed 
consent for continued participation as soon as his/her medical condition allows. The original signed ICF will be retained by the center and a copy of the signed and dated document and any other written in formation must be given to the person signing the form.  
Failure to obtain patient  consent will be reported by BSC to the applicable regulatory body 
according to their requirements (e.g., FDA requirement is within 5 working days of learning of such an event). Any violations of the informed consent process must be reported as deviations to the sponsor and local regulatory authorities (e.g. IRB /EC), as appropriate.  
If new information becomes available that can significantly affect a patient's future health and medical care, that information shall be provided to the affected patient (s) in w ritten form 
via a revised ICF or, in some situations, enrolled patients  may be requested to sign and date 
an addendum to the ICF. In addition to new significant information during the course of a study, other situations may necessitate revision of the ICF,  such as if there are amendments 
to the protocol, a change in Principal Investigator, administrative changes, or following annual review by the IRB /EC. The new version of the ICF must be approved by the IRB /EC. 
Boston Scientific approval is required if cha nges to the revised ICF are requested by the 
centerâ€™s IRB /EC. The IRB /EC will determine the patient  population to be re-consented. 
B.10.  Publication Policy  
 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 41 of 43 
 In accordance with the Corporate Policy on the Conduct of Human Subject Research, BSC 
requires disclosure of its involvement as a sponsor or financial supporter in any publication or presentation relating to a BSC study or its results. In accordance with the Corporate Policy for the Conduct of Human Subject Research, BSC will submit study results for publication (regardless of study outcome) following the conclusion or termination of the study. Boston Scientific Corporation adheres to the Contributorship Criteria set forth in the Uniform Requirements of the International Committee of Medical Journal Editors (ICMJE; http://www.icmje.org). In order to ensure the public disclosure of study results in a timely manner, while maintaining an unbiased presentation of study outcomes, BSC personnel may assist authors and investigators in publication preparation provided the following guidelines are followed.  
â€¢ All authorship and contributorship requirements as described above must be followed. 
â€¢ BSC involvement in the publication preparation and the BSC Publication Policy should be discussed with the Coordinating Pr incipal Investigator(s) and/or Executive/Steering 
Committee at the onset of the project.  
â€¢ The First and Senior authors are the primary drivers of decisions regarding publication content, review, approval, and submission.  
B.11.  Definitions of complication criteria  (per van der Gaag article):  
 Specific PBD (ERCP, PTC) related:  
 
â€¢ Acute pancreatitis :  Abdominal pain and a serum concentration of pancreatic enzymes 
(amylase or lipase) three or more times the upper limit of normal, that required more than 
one night of hospitalization  
â€¢ Acute cholecystitis :  No suggestive clinical or radiographic signs of acute cholecystitis 
before the procedure and if emergency cholecystectomy is subsequently required 
â€¢ Perforation:  Retroperitoneal or bowel-wall perforation documented by any radiographic technique or direct visual evidence  
â€¢ Stent Occlusion:  Recurring obstructive jaundice with necessary stent replacement  
Specific surgery related:  
 
â€¢ Pancreaticojejunostomy leakage:  Dr ain output of any measurable volume of fluid on 
or after postoperative day 3 with an amylase content greater than 3 times the serum 
amylase activity, graded according to clinical course (ISGPS grade A, B, C), or direct visual evidence of defect at anastomo sis  
â€¢ Delayed gastric emptying:  Gastric stasis requiring nasogastric intubation for 10 days or more, or the inability to tolerate a regular (solid) diet on or before the fourteenth 
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 42 of 43 
 postoperative day, not due to sequelae of intra- abdominal complications (i. e. abscess, 
anastomotic leakage)  
â€¢ Biliary leakage:  Bilirubin in abdominal drain or dehiscence found at laparotomy  
â€¢ Gastro/-duodenojejunostomy leakage:  Conclusive radiographic or direct visual 
evidence of a defect of the anastomosis  
â€¢ Intra -abdominal abscess formation:  Intra-abdominal fluid collection with positive 
cultures identified by ultrasonography or computed tomography, associated with 
persistent fever and elevations of white blood cells  
â€¢ Wound infection:  Requiring intervention otherwise considered as minor complication  
â€¢ Portal Vein Thrombosis:  Conclusive radiologic evidence of thrombosis  
 
Following either procedure:  
 
â€¢ Cholangitis:  Elevation in temperature more than 38Â°C, thought to have a biliary cause, without concomitant evidence of acute cholecystitis, requiring intervention  
â€¢ Hemorrhage :  Bleeding after the index procedure requiring transfusion of â‰¥4 units of 
packed cells within a 24-hour period, or leading to relaparotomy/intervention  
â€¢ (Emergency) (re)laparotomy:  Any (other) reason following either preoperative biliary 
drainage or another surgical procedure  
â€¢ Pneumonia :  Pulmonary infection with radiological confirmation and requiring antibiotic 
treatment  
â€¢ Mortality:  In -hospital death, due to protocol complications or any cause, including 
progression of disease, within the study period  
B.12 .  Abbreviations and Definitions  
 
B.12.1. Abbreviations 
Abbreviations are shown in Table 7.   
Table 7 : Abbreviations  
Abbreviation/Acronym  Term  
 
ADE  
AE 
BSC  
BTS 
CBD  
CI 
CRF  
CRO  
CT 
DFU  
eCRF   
Adverse Device Effect  
Adverse Event  
Boston Scientific Corporation  
Bridge to Surgery  
Common Bile Duct  
Confidence Interval  
Case Report Form  
Clinical Research Organization  
Computed Tomography  
Directions for Use  
Electronic Case Report Form  
E7034  Confidential  
14 SEP 2015  Boston Scientific 
FINAL   Pre-operative Biliary SEMS  
  RCT During Neoadjuvant Therapy 
  90905950 /Ver AE 
  Page 43 of 43 
 Table 7 : Abbreviations  
EDC  
ERCP  
EC 
FDA  
GCP  
ICF 
ICH 
ICMJE  
IDE 
IDR 
IRB 
ISO 
IVRS  
LFT 
MEDDEV  
MRI  
OUS  
PAL  
PD 
SADE  
SAE  
SEMS  
SUB -I 
UADE  
USA  
 Electronic Data Capture  
Endoscopic retrograde cholangiopancreatography  
Ethics Committee  
Food and Drug Administration  
Good Clinical Practices  
Informed Consent Form  
International Conference on Harmonization  
International Committee of Medical Journal Editors  
Investigational Device Exemption  
Independent Data Review Board  
Institutional Review Board  
International Organization for Standardization  
Interactive Voice Response System  
Liver Function Tests  
Medical Devices Directives  
Magnetic Resonance Imaging  
Outside of the United States  
Palliative  
Pancreaticoduodenectomy  
Serious Adverse  Device Effect  
Serious Adverse Event  
Self-Expanding Metal Stent  
Sub-Investigator  
Unanticipated Adverse Device Effect  
  United States of America  
 